We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-9.68%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$38.1M
Cap. Flow
+$16M
Cap. Flow %
4.71%
Top 10 Hldgs %
55.38%
Holding
79
New
17
Increased
14
Reduced
10
Closed
36

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$17.3M
2
IMVT icon
Immunovant
IMVT
+$10.9M
3
MRK icon
Merck
MRK
+$10.5M
4
GSK icon
GSK
GSK
+$10.3M
5
ACLX
Arcellx
ACLX
+$7.63M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$11.7M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$11.2M
3
ROIV icon
Roivant Sciences
ROIV
+$9.22M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$8.08M
5
INSM icon
Insmed
INSM
+$7.19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
51
PUT
Biohaven
BHVN
$2.13B
– –
-30,000
Closed -$122K
CABA icon
52
PUT
Cabaletta Bio
CABA
$435M
– –
-500,000
Closed -$1.07M
CGON icon
53
CG Oncology
CGON
$6.13B
– –
-40,723
Closed -$1.79M
CRGX
54
DELISTED
CARGO Therapeutics
CRGX
– –
-51,126
Closed -$1.14M
CRNX icon
55
PUT
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-175,000
Closed -$158K
DNTH icon
56
Dianthus Therapeutics
DNTH
$5.21B
– –
-43,456
Closed -$1.3M
FOLD
57
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-400,000
Closed -$120K
IMVT icon
58
CALL
Immunovant
IMVT
$8B
– –
-250,000
Closed -$319K
IRON icon
59
Disc Medicine
IRON
$2.81B
– –
-60,129
Closed -$3.74M
KRYS icon
60
PUT
Krystal Biotech
KRYS
$10.1B
– –
-20,000
Closed -$71K
LLY icon
61
Eli Lilly
LLY
$1.04T
– –
-15,067
Closed -$11.7M
MLTX icon
62
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-90,647
Closed -$4.55M
MRUS
63
PUT
DELISTED
Merus
MRUS
– –
-85,000
Closed -$213K
NAMS icon
64
NewAmsterdam Pharma
NAMS
$3.63B
– –
-80,334
Closed -$1.9M
RNAM
65
CALL
DELISTED
Avidity Biosciences
RNAM
– –
-75,000
Closed -$184K
ROIV icon
66
PUT
Roivant Sciences
ROIV
$24.4B
– –
-750,000
Closed -$56.3K
SLNO
67
DELISTED
Soleno Therapeutics
SLNO
– –
-115,833
Closed -$4.96M
SLRN
68
DELISTED
ACELYRIN
SLRN
– –
-714,773
Closed -$4.82M
TARA icon
69
CALL
Protara Therapeutics
TARA
$229M
– –
-87,900
Closed -$13.2K
TARS icon
70
Tarsus Pharmaceuticals
TARS
$2.52B
– –
-222,253
Closed -$8.08M
TARS icon
71
PUT
Tarsus Pharmaceuticals
TARS
$2.52B
– –
-50,000
Closed -$41.3K
TRML
72
DELISTED
Tourmaline Bio
TRML
– –
-274,219
Closed -$6.28M
TSHA icon
73
Taysha Gene Therapies
TSHA
$1.72B
– –
-1,087,785
Closed -$3.12M
UTHR icon
74
CALL
United Therapeutics
UTHR
$22.5B
– –
-10,000
Closed -$10.8K
VERA icon
75
PUT
Vera Therapeutics
VERA
$2.81B
– –
-40,000
Closed -$75K
1 2
3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Stempoint Capital held 79 positions worth $340M, down 10% from $378M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Stempoint Capital deployed $16M of net new capital in Q2 2024, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Immunocore: 339,351 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $11.2M trimmed.

  • Stempoint Capital's largest Q2 2024 buy was Immunocore: 339,351 shares worth $11.5M.
  • Stempoint Capital added most to Immunovant in Q2 2024, an estimated $10.9M increase.
  • Stempoint Capital's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $11.2M.
  • Stempoint Capital fully exited Eli Lilly in Q2 2024, selling an estimated $11.7M.
  • Stempoint Capital's ten largest holdings make up 55% of its $340M portfolio in Q2 2024.
  • Stempoint Capital opened 17 new positions and closed 36 in Q2 2024.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $340M.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.